News

Investor's Business Daily on MSN2h
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot ...
InvestorsHub on MSN3h
Apogee Therapeutics Shares Surge After Promising Eczema Drug Trial Results
Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) soared 24% in Monday’s session following encouraging results from its Phase ...
Fierce Biotech4h
Apogee claims IL-13 antibody sets new eczema treatment standard in phase 2 study
Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial
Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...